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Abstract
Background aims. Tracking cells during regenerative cytotherapy is crucial for monitoring their safety and efficacy. Mac-
rophages are an emerging cell-based regenerative therapy for liver disease and can be readily labeled for medical imaging.
A reliable, clinically applicable cell-tracking agent would be a powerful tool to study cell biodistribution. Methods. Using a
recently described chemical design, we set out to functionalize, optimize and characterize a new set of superparamagnetic
iron oxide nanoparticles (SPIONs) to efficiently label macrophages for magnetic resonance imaging–based cell tracking in
vivo. Results. A series of cell health and iron uptake assays determined that positively charged SPIONs (+16.8 mV) could
safely label macrophages more efficiently than the formerly approved ferumoxide (−6.7 mV; Endorem) and at least 10 times
more efficiently than the clinically approved SPION ferumoxytol (−24.2 mV; Rienso). An optimal labeling time of 4 h at
25 μg/mL was demonstrated to label macrophages of mouse and human origin without any adverse effects on cell viability
whilst providing substantial iron uptake (>5 pg Fe/cell) that was retained for 7 days in vitro. SPION labeling caused no
significant reduction in phagocytic activity and a shift toward a reversible M1-like phenotype in bone marrow–derived mac-
rophages (BMDMs). Finally, we show that SPION-labeled BMDMs delivered via the hepatic portal vein to mice are localized
in the hepatic parenchyma resulting in a 50% drop in T2* in the liver. Engraftment of exogenous cells was confirmed via
immunohistochemistry up to 3 weeks posttransplantation. Discussion. A positively charged dextran-coated SPION is a prom-
ising tool to noninvasively track hepatic macrophage localization for therapeutic monitoring.
KeyWords: cell therapy, cell tracking, liver fibrosis, macrophage,MRI
Introduction
Cell-based therapy offers an exciting new approach
in the field of regenerative medicine to treat a range
of diseases.Tracking cells after transplantation through
medical imaging is considered an indispensable tool
to ensure appropriate cell localization, migration and
engraftment in the host tissue.There is a pressing need
to develop new techniques to noninvasively detect and
track transplanted cells in vivo using sensitive and safe
tracking agents. Superparamagnetic iron oxide
nanoparticles (SPIONs) are a versatile class of
magnetic resonance imaging (MRI)-based contrast
agents that have been used clinically to detect
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hepatocellular carcinomas in patients [1,2] and have
potential as magnetic fluid hyperthermia treatment for
cancers as well as magnetic targeting of drugs [3].More
recently, several reports have successfully employed
SPIONs as a means to label cells in vitro (primarily
macrophages, which readily ingest SPIONs) before
transplantation and subsequently track cells via MRI
[4,5]. Obtaining sufficient iron uptake in cells is a chal-
lenge and the limiting factor for MRI sensitivity. To
improve uptake, several approaches have been used
previously, including post-modification steps [6] or use
of transfection agents [7], which can elicit toxicity [8].
In 2009, two clinically approved SPIONs were removed
from the market for commercial reasons, ferumoxide
(Endorem, Guerbet) and ferucarbotran (Resovist,
Schering). Ferumoxytol (Rienso,Takeda/AMAG Phar-
maceuticals) is still available clinically for the treatment
of anemia in parts of Asia and the United States, but
not in Europe.Therefore, there is currently a lack of
suitable MRI-based contrast agents that can be used
in both the laboratory and the clinic for cell-tracking
purposes.
Our group recently described a technique to syn-
thesize SPIONs with a modified dextran coating that
contains diethylaminoethyl (DEAE) and fluorescein
isothiocyanate (FITC) moieties that confer a posi-
tive charge and green fluorescent properties (GFPs)
to the nanoparticles, respectively [9]. Chemically and
structurally, the novel SPIONs are comparable to the
formerly clinically approved SPIONs in having a
dextran-coating and a similar sized iron core of ap-
proximately 60 nm. Here, we have used these novel
SPIONs to label macrophages of murine and human
origin.Macrophages represent a promising cell therapy
for the treatment of liver fibrosis by reducing fi-
brotic scarring and improving liver regeneration and
function through several mechanisms, including the
expression of metalloproteinase enzymes, which
degrade fibrotic scars, clearance of cellular debris and
increased expression of cytokines implicated in the re-
generative processes of the liver such as vascular
epithelial growth factor [10,11]. Phase I/II clinical trials
are currently in progress (MacrophageTherapy for Cir-
rhosis [MATCH] study).The availability of a suitable
cell-tracking agent for macrophage therapy would po-
tentially complement the design of prospective clinical
trials and support clinical use by monitoring appro-
priate localization and engraftment of cells in the host.
Therefore, to assess whether the SPIONs are suit-
able MRI-based contrast agents for macrophage
therapy, we have performed a series of investigations
to examine the effect of SPION-labeling on these cells.
Primary macrophages were differentiated in vitro from
mouse bone marrow (bone marrow–derived mac-
rophages [BMDMs]) or from human monocytes
(monocyte-derived macrophages [hMDMs]) using
defined protocols. Both sources provide highly en-
riched populations of mature and functionally active
macrophages as previously reported [10,12]. Our group
has recently described a method to control the syn-
thetic approach to change the size and electrostatic
charge of dextran-coated SPIONs [9]. Here we have
investigated how modulation of these physicochemi-
cal properties at the particle level can influence the
suitability of these molecules as macrophage con-
trast agents. Hence, macrophages were labeled with
either novel functionalized SPIONs, previously clin-
ically approved, or clinically approved SPIONs that
served as comparators. Safety studies (cell viability/
cytotoxicity) and iron uptake experiments were
performed with respect to dose and time to identify
the most appropriate labeling protocol in these cells.
Due to the plasticity of macrophages, we further sought
to test whether iron labeling caused any change in cell
phenotype or function. Finally, we performed a lon-
gitudinal MRI study to monitor the biodistribution
of SPION-labeled BMDMs in vivo after transplan-
tation. In this way, we have been able to show that
macrophages localize into the liver parenchyma after
transplantation, which can be monitored for several
weeks.We have thus developed a SPION that can ef-
ficiently label macrophages, is biocompatible and can
serve as a suitable tracking agent to noninvasively
monitor hepatic localization of macrophages in vivo.
Methods
BMDMs
Femurs and tibias of C57/BL6 male mice (8–10 weeks
old) were collected in Hank’s Balanced Salt Solu-
tion (Gibco) containing penicillin/streptomycin. In a
sterile fume hood, muscle tissues were removed. Bone
marrow was flushed out with Dulbecco’s Modified
Eagle’s Medium (DMEM):F12 (1:1) cell culture media
(Gibco) supplemented with 10% fetal bovine serum
(v/v), 1 × glutamine and 1 × penicillin/streptomycin.
Mouse bone marrow was centrifuged (400g, 5 min)
and then resuspended in fresh supplemented
DMEM:F12 media (20 mL) containing 20 ng/mL
murine recombinant macrophage colony-stimulating
factor (mCSF; Peprotech). Bone marrow suspen-
sions were then transferred to sterile ultra-low
attachment flasks (Corning) and incubated at 37°C,
5% CO2. Every second day, 10% of the media was
replaced with fresh media containing 400 ng mCSF.
After 7 days, mature macrophages were fully differ-
entiated (as determined by fluorescence-activated cell
sorting [FACS]/morphological assessment) and sub-
sequently used for iron-labeling experiments. In some
experiments, BMDMs were primed toward an M1-
or M2-like phenotype by the overnight addition of re-
combinant murine interferon-γ (PeproTech) and
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lipopolysaccharides (lipopolysaccharides from Escheri-
chia coli; Sigma) or recombinant murine interleukin
(IL)-4 (PeproTech; M1 and M2, respectively).
hMDMs
CD14+ monocytes were harvested via apheresis from
healthy volunteers as described in Moore et al. [12].
Monocytes were frozen in liquid nitrogen in
cryopreservation solution. For SPION-labeling ex-
periments, high-density monocyte aliquots were
defrosted in a water bath, washed, and resuspended
in Iscove’s Modified Eagle Medium supplemented with
10% fetal bovine serum and 100 ng/mL human re-
combinant mCSF (Miltenyi) in low-attachment flasks
(Corning) at 2 × 106 monocytes/mL for 7 days, re-
placing mCSF every second day.After 7 days, hMDMs
were harvested as described, counted and incubated
overnight in 96-well plates (4 × 104/well) before via-
bility studies were performed.
SPION labeling of macrophages
SPIONs were synthesized as described in supplemen-
tary methods. Ferumoxytol (Rienso, Takeda
Pharmaceuticals) was sourced fromTakeda Pharma-
ceuticals [13]. SPIONs were diluted in fresh
supplemented media (as described) containing 1% fetal
bovine serum (v/v) and immediately applied to cells
at the appropriate doses (0–100 μg Fe/mL) and times
(0–168 h) in microplates. Cell health assessments were
performed independently by two investigators to ensure
reproducibility.
Cell viability and cytotoxicity analysis
Cell viability and cytotoxicity was assessed by mea-
surement of cellular adenosine triphosphate (ATP)
content using CellTiter-Glo Luminescent Cell
Viability Assay (Promega) and the Cytotoxicity De-
tection Kit based on lactate dehydrogenase leakage
(LDH) (Roche) according to the manufacturer’s
instructions.
Iron uptake quantification (ferrozine assay)
Cellular iron levels were determined using an assay
based on previously reported work [14,15]. Briefly,
cells were lysed in 1.2 mol/L HCl (50 μL) and de-
tached from the plate surface using a pipette tip.
Acidified cell lysates were transferred into microtubes
and digested at 65°C for 2 h. Lysates were allowed
to cool and then diluted with dH20 (1:1). Ferrozine
reagent (30 μL–5 mol/L ammonium acetate, 2 mol/L
ascorbic acid, 6.5 mmol/L 3-(2-Pyridyl)-5,6-diphenyl-
1,2,4-triazine, 15 mmol/L neocuproine) was added to
each sample, vortexed and allowed to equilibrate for
30 min to allow color development. Absorbance was
measured at 570 nm on a microplate reader (Fluostar
Omega, BMG Labtech). A standard curve was used
using known iron standards (Sigma Aldrich), and
samples were interpolated from the standard curve to
quantify iron content per cell.
Prussian blue staining
Cellular iron content was visualized using the Prus-
sian blue stain as outlined in supplementary methods.
Gene expression analysis
The expression of a number of mRNAs chosen for
their role in macrophage polarization were quanti-
fied using quantitative polymerase chain reaction.The
following primers messenger RNAs were detected: IL-
1b, IL-12b, IL-10, tumor necrosis factor (TNF)-α,
CD206 (MRC), Arg-1, Chi3L3 (QuantiTect Primer
Assay, Qiagen). Each sample was measured in trip-
licate and normalized to glyceraldehyde-3-phosphate
dehydrogenase.
Flow cytometry
To assess the phagocytic ability of BMDMs incu-
bated with SPIONs, BMDMs were incubated with
fluorescently labeled Saccharomyces cerevisiae (Zymosan
A S. cerevisiae BioParticles, Texas Red conjugated,
ThermoFisher Scientific). Flow cytometry was also
used to assess the cell surface markers CD86 and
CD206 on BMDMs.
Transplantation and MRI
For cell-tracking studies, BMDMs were differenti-
ated as described from 10-week-old male mice that
constitutively express activated enhanced GFP
(aEGFP) under a phosphoglycerate kinase (PGK) pro-
moter on a C57BL6/J background (see Gilchrist et al.)
[16]. BMDMs were counted and incubated with
SPION (DEAE-Dex 1:4) for 4 h at 25 μg Fe/mL in
low-attachment flasks. SPION-labeled BMDMs
(1 × 106) were transplanted via the hepatic portal vein
(HPV) of healthy wild-type C57BL6/J male mice.The
HPV was accessed via midline laparotomy using aseptic
technique.Anesthesia was induced and maintained with
gaseous oxygen/isofluorane. After injection, the peri-
toneal wall and skin were sutured. Buprenorphine
(0.05 mg/kg, subcutaneous) was given for analgesia
with saline (500 μL, subcutaneous). Experimental
animal protocols were performed in accordance with
the approved guidelines under a license granted under
the Animals (Scientific Procedures) Act 1986 and ap-
proved by the University of Edinburgh Animal Ethics
Committee.
MRI was performed the day before transplanta-
tion (n = 4, baseline measurements).The same mice
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were scanned again on days 6 (n = 4), 13 (n = 3), 20
(n = 2) and 27 (n = 1) post-transplantation to monitor
biodistribution over 4 weeks, the timeframe through
which macrophages have been described to provide
therapeutic action. One mouse was culled per time
point for histological assessment. Anesthetized mice
were scanned on a 7T Agilent MRI using a 33-mm
inner diameter radiofrequency coil for signal trans-
mission and reception. For T2* mapping, images
were acquired in axial orientation using a respiratory-
gated gradient echo sequence with the following
parameters: repetition time 60 ms; echo time 1, 2, 3,
5, 7, 9, 12 and 15 ms, matrix size 128 × 128, field of
view 35.0 × 35.0 mm, flip angle 15°, slice thickness
2 mm and two signal averages. Axial sections were
taken from the upper abdomen (to capture mainly
liver) and lower abdomen (to capture several abdom-
inal organs). Three regions of interest (ROIs) were
taken from each organ to quantify an average
mean. T2* maps were generated and quantified in
FIJI [17] using the MRI Analysis Calculator
plug-in.
Immunohistochemistry
Detection of EGFP was performed on unfixed frozen
sections. Briefly, 7-μm sections were cut on a cryo-
stat and collected on SuperFrost Plus slides and
fixed according to Jockusch et al., using formalde-
hyde vapor fixation [18]. Sections were washed for
5 min with phosphate buffered saline, and blocked
with a protein block (Spring Bioscience) for 30 min
at room temperature. Sections were then incubated
with polyclonal goat anti-GFP (1:200) for 60 min at
room temperature, extensively washed and then in-
cubated with donkey anti-goat Alexa 488 (1:300,
Life Technologies) for 1 h in a dark environment.
Slides were mounted with 4′,6-diamidino-2-
phenylindole (DAPI)-fluoromount G, and were
examined under a fluorescence microscope (Nikon
Eclipse E600). Negative controls were obtained by
omission of the primary antibody or using isotype
goat immunoglobulin G (1:200) instead of the primary
antibody. Cryosections from aEGFP liver served as
a positive control.
Statistical methods
Data points are presented as the mean value around
the standard deviation, unless otherwise stated. Sta-
tistical analysis was performed in GraphPad Prism 6
(Graphpad Software). Data sets were tested for nor-
mality using the Shapiro-Wilk test. For tests containing
two groups, a Student’s t-test was performed; a one-
way analysis of variance was performed for tests
containing more than two groups.
Additional methods
Additional and more detailed methods are provided
in supplementary materials.
Results
Clinically approved SPIONs are biocompatible with
BMDMs
Two clinically approved SPIONs (ferumoxide and
ferumoxytol) were incubated with murine BMDMs
to assess their effect on cell health and the degree of
uptake by BMDMs. BMDMs were incubated with
ferumoxide or ferumoxytol over a range of concen-
trations (0–100 μg/mL) for 24 h. None of the
commercial SPIONs caused any significant reduc-
tion in cell viability as assessed by ATP activity
(Figure 1A) or significant cell death as assessed by
LDH release (Figure 1B). BMDMs incubated with
ferumoxytol had a peak iron content of 1.3 pg Fe/
cell whereas ferumoxide had peak iron contents of
7.6 pg Fe/cell respectively (Figure 1C).
Biocompatibility and iron uptake of dextran-coated
SPIONs depends on surface charge
To determine the optimal parameters required for iron
labeling in macrophages, we designed, synthesized and
tested three dextran particles as described in Table I.
The three particles had a neutral surface charge (Dex),
a positive surface charge (DEAE-Dex 4:1) or a neg-
ative surface charge (CM-Dex) [20] and were
incubated with BMDMs for 24 h over a range of con-
centrations (0–100 μg/mL). Dex and CM-Dex caused
significant reductions in cell viability at 75 μg/mL (59%
and 65%, respectively) and 100 μg/mL (50% and 54%,
respectively) as determined by the ATP assay. DEAE-
Dex 4:1 ratio caused significant reductions in cell
viability at 50, 75 and 100 μg/mL (38%, 26% and 20%
respectively) (Figure 2A). Dex and CM-Dex caused
no significant increases in cell death as determined by
the LDH assay (Figure 2B), whereas DEAE-Dex 4:1
caused significant increases in cell death at 75 and
100 μg/mL (34% and 37% respectively). However, Dex
and CM-Dex only modestly labeled BMDMs pro-
viding peak cellular iron contents of 0.3 and 0.6 pg
Fe/cell respectively, whereas DEAE-Dex 4:1 caused
a substantial dose-dependent increase in iron content,
which reached 3.1 pg Fe/cell (Figure 2C).
Biocompatibility and iron uptake of dextran-coated
SPIONs depends on core size
Because the positively charged dextran-coated SPIONs
(DEAE-Dex 4:1) provided the best uptake, we next
altered the core size of the positively charged SPION
to further improve labeling efficiency in BMDMs
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Figure 1. Biocompatibility of clinically approved SPIONs. Cell health (A and D), cytotoxicity (B and E) and intracellular iron content (C
and F) assays in murine BMDMs incubated with three commercial SPIONs for 24 h or human MDMs incubated with ferumoxide only.
Macrophages were incubated with either ferumoxide (black lines) or ferumoxytol (gray lines) as indicated in the panels. Bars show the
mean value per group around the standard deviation (error bars). Statistical significance (P) to respective controls (0 μg/mL SPION) was
determined by a one-way analysis of variance and indicated by P values in corresponding colors to the lines.
Table I. Summary of various SPIONs used in this current study, dextran polymers used, polymer-to-iron ratio and the resultant hydro-
dynamic size and surface charge.
Polymer type
Polymer-to-iron
salt ratio
Hydrodynamic
diameter (nm)
Surface
charge (mV)
Intracellular iron content
after 4 h labeling (pg)
(25 μg/mL labeling)
Intracellular iron content
after 24-h labeling (pg)
(25 μg/mL labeling)
Dextran 4:1 36.0 −3.3 N/A 0.3
CM-dextran 4:1 34.3 −11.6 N/A 0.5
DEAE-dextran 4:1 39.7 +19.6 N/A 2.0
DEAE-dextran 1:1 47.3 +17.7 N/A 2.3
DEAE-dextran 1:4 68.0 +16.8 7.4 9.1
Ferumoxide Unknown 115 −6.7 2.2 4.9
Ferumoxytol Unknown 24.9 −24.2 0.1 0.9
Further information on commercial SPIONs can be found in a review by Li et al. [19].
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(Table I). Three SPIONs were synthesized with in-
creasing hydrodynamic diameter using different ratios
of DEAE and dextran (DEAE-Dex 4:1, DEAE-Dex
1:1 and DEAE-Dex 1:4) [19].These candidates were
incubated with BMDMs for 24 h. DEAE-Dex 1:1 and
DEAE-Dex 1:4 caused significant reductions in cell
viability at 50 (42% and 62%, respectively), 75 (40%
and 56%, respectively) and 100 μg/mL (23% and 51%,
respectively) as determined by the ATP assay
(Figure 2D). However, neither DEAE-Dex 1:1 nor
DEAE-Dex 4:1 caused any significant increase in cell
death as determined by the LDH assay (Figure 2E).
DEAE-Dex 1:1 led to intracellular iron levels that
reached 3.1 pg Fe/cell, and DEAE-Dex 1:4 led to a
dose-dependent increase in intracellular iron levels that
reached 11.3 pg Fe/cell (Figure 2F).
Reducing labeling time of DEAE-Dex 1:4 improves
biocompatibility and labels macrophages at sufficient
iron levels required for MRI
We next investigated DEAE-Dex 1:4 further with
varying incubation times with BMDMs, from 4 h up
to 48 h, and also 7 days after a 24-h labeling period
(Figure 3A–J). A 4-h incubation caused no signifi-
cant decrease in cell viability or increase in cytotoxicity,
resulting in a peak cellular iron content of 5.4 pg Fe/
cell. A 24-h incubation with DEAE-Dex 1:4 caused
significant reductions in cell viability (Figure 3A) at
50, 75 and 100 μg/mL (61%, 56% and 51% respec-
tively) and significant increases in cell death (Figure 3B)
at 75 and 100 μg/mL (19.7% and 23%, respective-
ly). A 48-h incubation caused significant reductions
Figure 2. Biocompatibility of SPIONs is dependent on surface charge and iron core size. Cell health (A and D), cytotoxicity (B and E)
and intracellular ion content (C and F) of BMDMs incubated with dextran coated SPIONs with varying surface charges (A–C) or a pos-
itive surface charge and varying iron core sizes (D–F).The positively charged DEAE-Dex 4:1 (A–C; black lines), the neutral 4:1 Dex (A–
C; light gray lines) and the negatively charged CM-Dex 4:1 (A–C; gray lines) were incubated with BMDMs.The DEAE-Dex 4:1 (D–F;
black lines) has a hydrodynamic diameter of 39.7 nm, the 1:1 Dex (D–F; light gray lines) 47.3 nm and the DEAE-Dex 1:4 (D–F; gray
lines) 68 nm. Statistical significance (P) to respective controls (0 μg/mL SPION) was determined by a one-way analysis of variance and
indicated by P value in corresponding color to lines.
ARTICLE IN PRESS
6 J. Sharkey et al.
Q6
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
in viability at 75 and 100 μg/mL (51% and 40%, re-
spectively) and significant increases in cell death at 75
and 100 μg/mL (31.6% and 31.9%, respectively). Iron
uptake (Figure 3C) showed a dose-dependent in-
crease in both 24-h and 48-h incubations with peak
cellular iron contents of 11.3 and 14.3 pg Fe/cell, re-
spectively. Prussian blue staining of BMDMs shows
intracellular iron at 4, 24, 48 and 7 days post-24-h
incubation with DEAE-Dex 1:4 (Figure 3D–G).
Because a 4-h incubation of DEAE-Dex 1:4 at
25 μg/mL provided substantial iron-labeling but caused
no change in any index of cell health, we proceeded
to investigate cell health and iron content up to 7 days
post-labeling compared with ferumoxide (at 25 μg/
mL) and ferumoxytol (at 100 μg/mL to promote iron
labeling). Using this labeling protocol, we observed
no drop in ATP (Figure 3H) levels at any time with
any of the SPIONs tested. Interestingly, we ob-
served an approximate twofold to threefold increase
in ATP levels post-labeling peaking at 72–96 h after
labeling with all three SPIONs. However, we have also
observed this effect in unlabeled BMDMs, and there-
fore there was no difference over controls (data not
shown), which suggests this is a function of the natural
changes in BMDM physiology during the course of
in vitro culture.
Furthermore, we observed no increase in LDH
leakage at any time point in BMDMs labeled with
DEAE-Dex 1:4 in contrast to the comparator SPION,
ferumoxytol, which caused a twofold increase
(Figure 3I). However, the ATP data suggest that the
cells are still viable at this time point (Figure 3H),
and therefore the increase in LDH leakage might be
due to increased metabolic activity rather than overt
cytotoxicity per se. Iron labeling in BMDMs labeled
with DEAE-Dex 1:4 outperformed the comparator
SPIONs with cellular iron levels of 4.8 pg/cell at 7
days compared with 2.3 and 0.8 pg Fe/cell for
ferumoxide and ferumoxytol, respectively (Figure 3J).
BMDMs labeled with DEAE-Dex 1:4 had 46% less
cellular iron at 7 days (4.8 pg Fe/cell) compared
with the maximum labeling level at 12 h (8.9 pg
Figure 3. Biocompatibility of SPIONs is dependent on labeling time in murine and human macrophages. Cell health (A), cytotoxicity (B)
and intracellular ion content (C) of BMDMs incubated with DEAE-Dex 1:4 for either 4 h (black lines), 24 h (light gray lines) or 48 h
(gray lines). Prussian blue staining shows intracellular iron after a 4-hour (D), 24-hour (E) and 48-hour (F) incubation and 7 days post-
24-h incubation (G). A 7-day time course study was performed in BMDMs labeled for 4 h with DEAE-Dex 1:4 (black lines), ferumoxide
(gray lines), or ferumoxytol (light gray lines) and then replaced with normal media to determine cell viability (H), cytotoxicity (I), and
iron labeling (J). (K–M) Human MDMs were incubated with DEAE-Dex 1:4 for 4 h (black lines) or 24 h (light gray lines) to determine
cell viability (K), cytotoxicity (L) and iron labeling (M). Statistical significance (P) to respective controls (0 μg/mL SPION) was deter-
mined by a one-way analysis of variance and indicated by P values in corresponding colors to lines.
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Fe/cell), suggesting excretion of SPIONs. Neverthe-
less, we found this iron concentration sufficient to
provide MRI contrast.
To evaluate the biocompatibility of DEAE-Dex
1:4 in hMDMs, we incubated this SPION for 4 and
24 h (Figures 1D–F, 3K–M). Similar to murine
BMDMs, there was a time- and dose-dependent tox-
icity evident. ATP levels dropped 18%, 50% and 76%
at 50, 75 and 100 μg/mL, respectively (Figure 3K).
This effect was pronounced at 24 h with ATP levels
dropping 87%, 92.6% and 96% at the same concen-
trations. Cytotoxicity was also evidenced through LDH
release which increased 1.4-fold at 100 μg Fe/mL after
4-h incubation but 4.3-fold after 24-h incubation at
the same concentration (Figure 3L). However, iron
labeling was more variable between wells in hMDMs,
probably due to toxicity being a confounding factor
in these cells, which were more sensitive to SPION
treatment. In hMDMs, we observed an iron content
of 5.6 pg Fe/cell at 25 μg/mL after 4 h (Figure 3M).
An iron content of 2.9 pg Fe/cell was measured after
24-h labeling at the equivalent SPION concentra-
tion suggesting cell death was reducing the average
measurement of iron across the population. There-
fore, a reduced labeling time of 4 h at 25 μg/mL
provides efficient iron labeling that is well tolerated
in murine and human macrophages and is well re-
tained for 7 days in vitro.
The effect of incubation with DEAE-Dex 1:4 on
BMDM function and phenotype
To determine whether DEAE-Dex 1:4 incubation and
subsequent uptake by BMDMs affected their func-
tion, the phagocytic ability was assessed. BMDMs were
incubated with dextran-coated SPIONs and
ferumoxytol for 24 h followed by incubation with
fluorescently labeled S. cerevisiae and assessed by either
FACS or microscopy. Incubation with 10, 25 or 50 μg/
mL DEAE-Dex 4:1 caused no significant reduction
in the fraction of fluorescently labeled cells as as-
sessed by FACS (Figure 4F). However, incubation with
100 μg/mL ferumoxytol caused significant reduc-
tions in the fraction of labeled cells (45.6%).
Microscopy images also show that ferumoxytol
(Figure 4B) leads to fewer yeast containing cells.
After this, the effect of DEAE-Dex 1:4 on BMDM
phenotype was investigated by assessing the expres-
sion of the cell surface markers, CD86 and CD206,
and also by quantifying the expression of a number
of mRNAs which are indicative of an M1-like (IL-
1b, IL-12b,TNFα) or M2-like (CD206, IL-10, Arg-
1, Chi3l3) phenotype. The expression of CD86
increased in a dose-dependent manner when incu-
bated with 10, 25 or 50 μg/mL DEAE-Dex 1:4.This
increase in CD86 expression could be significantly
reduced to 48.9% and 57.2% at 25 and 50 μg/mL,
Figure 4. Immunofluorescence images showing differently treated BMDMs incubated with S. cerevisae particles conjugated to Texas red
(red) for 2 h and subsequently stained with DAPI (blue). Extracellular fluorescence was quenched with 0.4% trypan blue. BMDMs were
either not treated (A), treated with 100 μg/mL ferumoxytol (B), 10 μg/mL DEAE-Dex 1:4 (C), 25 μg/mL DEAE-Dex 1:4 (D) or 50 μg/
mL DEAE-Dex 1:4 for 24 h before staining. The aforementioned treated cells were also analyzed using FACS to detect the fraction of
cells that possessed intracellular fluorescence (F). Statistical significance (P) to respective controls (0 μg/mL SPION) was determined by
a one-way analysis of variance and indicated by P values in corresponding colors to lines.
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respectively, if BMDMs were incubated with IL-4 for
24 h post-labeling with DEAE-Dex 1:4 (Figure 5A).
The expression of CD206 was decreased in re-
sponse to 10, 25 and 50 μg/mL DEAE-Dex 1:4
(Figure 5B). However, this decrease could be re-
versed by incubation with IL-4 after DEAE-Dex
labeling to 83.6%, 84.1% and 79.7% for 10, 25 and
50 μg/mL DEAE-Dex 1:4.
mRNA expression of the M1-like phenotypic
markers IL-1b, IL-12b andTNFα were significantly
increased post-incubation with lipopolysaccharides and
interferon-γ and increased when incubated with 10,
25 or 50 μg/mL DEAE-Dex 4:1. Expression of IL-
1b, IL-12b andTNFα was decreased if BMDMs were
incubated with IL-4 post-labeling with DEAE-Dex 1:4
(Figure 6A,B,D).The mRNA expression of the M2-
like markers IL-10, CD206, Arg1 and Chi3L3 were
significantly elevated post incubation with IL-4.The
expression of the CD206 and Arg1 were decreased
post-incubation with DEAE-Dex 1:4, whereas IL-
10 and Chi3L3 remained relatively unchanged. The
decreases in the expression of CD206 and Arg-1 were
reversed by post-incubation with IL-4 for 24 h post-
labeling with DEAE-Dex 1:4 (Figure 6C,E,F).
Noninvasive MRI-based detection of SPION-labeled
BMDMs in vivo
To test whether SPION-labeled BMDMs could be de-
tected in vivo via MRI, we designed a biodistribution
study.We labeled BMDMs using a protocol (25 μg Fe/
mL, 4 h) that was well-tolerated and provided
substantial iron loading. BMDMs were differenti-
ated from bone marrow harvested from double
homozygous aEGFP-97 mice that express EGFP con-
stitutively and ubiquitously, including in macrophages
[16]. FACS analysis showed that BMDMs (CD45+,
CD11b, F4/80+ve) from aEGFP mice were 98% GFP-
positive (supplementary Figure S4). SPION-labeled
EGFP-positive BMDMs were transplanted (1 × 106)
toWT mice via the hepatic portal vein to mirror the
number of cells and dosing route required for liver fi-
brosis therapy [10]. Mice were scanned before
(baseline) and after (at 6, 13, 20 and 27 days) trans-
plantation. The residual injectate was retained and
placed back in culture for 48 h. Immunocytochem-
istry and Prussian blue staining confirmed that donor
cells were viable, expressed GFP and were iron-rich
as expected (supplementary Figure S4A,B).
MRI maps from axial sections of the abdomen in
T2* scanning format showed an average 50% drop
in liver T2* time after 6 days (versus baseline), in-
dicative of hepatic localisation of SPION-labeled
BMDMs (Figure 7A).The drop inT2* intensity was
uniform throughout the liver in axial sections of the
lower (Figure 7A) and upper (supplementary
Figure S5A) abdomen.The same animals were scanned
again at days 13, 20 and 27 (one animal culled per
time point) post-transplantation.The reduction inT2*
was maintained throughout the course of the study
with 42%, 56% and 49% lowerT2* values at days 13,
20 and 27, respectively. Furthermore, this decrease in
T2* was restricted to the liver with no differences re-
corded in kidney or muscle tissue (Figure 7B). T2*
Figure 5. FACS analysis of CD86 (A) and CD206 (B) in differently treated BMDMs. BMDMs were either treated for 24 h with media
containing MCSF-1 only (control macrophages), primed toward an M1-like phenotype, primed toward an M2-like phenotype, incubated
with DEAE-Dex 1:4 alone or DEAE-Dex 1:4 followed by priming toward an M2-like phenotype for 24 h. BMDMs were either not labeled
with DEAE-Dex 1:4 (black bars), or labeled with DEAE-Dex 1:4 at concentrations of 10 μg/mL (white bars), 25 μg/mL (light gray bars)
or 50 μg/mL (dark gray bars). Statistical significance (P) was determined by a one-way ANOVA and indicated by P values. P values com-
pared with M0 macrophages.
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Figure 6. mRNA expression of genes that may suggest an M1- or M2-like phenotype in BMDMs treated with various conditions. The
expression of IL-1b (A), IL-12b (B), IL-10 (C),TNF-α (D), CD206 (E), Arg-1 (F) and Chi3L3 (G) were quantified. BMDMs were either
treated for 24 h with media containing MCSF-1 only (control macrophages), primed toward an M1 like phenotype, primed toward an
M2-like phenotype, incubated with DEAE-Dex 1:4 alone or DEAE-Dex 1:4 followed by priming toward an M2 like phenotype for 24 h.
BMDMs were either not labeled with DEAE-Dex 1:4 (black bars), or labeled with DEAE-Dex 1:4 at concentrations of 10 μg/mL (white
bars), 25 μg/mL (light gray bars) or 50 μg/mL (dark gray bars). Statistical significance (P) was determined by a one-way analysis of vari-
ance and indicated by P values. P values compared to M0 macrophages.
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maps of the upper abdomen showed a similar trend
with a 59%, 57%, 50% and 45% reduction inT2* time
at days 6, 13, 20 and 27 (versus baseline)
(supplementary Figure S5A,B).These data also suggest
a slight increase inT2* relaxation time over the course
of the study indicative of clearance of iron and/or cells
from the liver.
To confirm the hepatic localization, we
performed Prussian blue staining and immunohisto-
chemistry versus EGFP to detect exogenous cells in
the liver. Prussian blue stains exhibited cellular punc-
tate iron deposits throughout the liver parenchyma at
all time points analyzed (Figure 8A). No iron depos-
its were observed in normal mouse liver or in liver that
had unlabeled BMDMs transplanted. Furthermore,
IHC versus EGFP on frozen liver sections showed GFP
positive cells in the liver at days 6, 13 and 20. No GFP
positivity was detected at day 27 suggesting possible
clearance of BMDMs from the liver, similar to find-
ings observed byThomas et al., and possible transfer
of iron to host cells [10].
Discussion
The emerging field of cell-based regenerative medi-
cine opens new therapeutic avenues for the treatment
of a range of diseases. Unlike traditional therapies using
small molecules, cells have the propensity to migrate,
engraft and integrate with host tissue to exert a ther-
apeutic effect.Therefore, it is important to understand
the biodistribution and pharmacokinetics of donor cells
in the host tissue to monitor both the safety and ef-
ficacy of treatment. Medical imaging can be used to
track cells post-transplantation, and a range of imaging
modalities has been described to this end (for review,
see Naumova et al.) [21]. One attractive approach uses
MRI, a versatile, noninvasive method that offers high-
resolution multidimensional imaging while providing
translation of data between human and preclinical
species. In this setting, contrast agents can be used
to label cells in vitro before transplantation to provide
visualization of donor cells in the host. Several iron-
based contrast agents (e.g., SPIONs) have previously
been used to directly label cells for cell tracking due
to their high biocompatibility, high sensitivity and rel-
atively simple labeling procedure [5,22,23]. However,
as of 2016, three clinically approved SPIONs
ferumoxide (Endorem, Feridex), ferucarbotran
(Resovist, Cliavist) and ferumoxtran (Sinarem,
Combidex) have all been discontinued for commer-
cial reasons, resulting in a lack of suitable contrast
agents to continue the evaluation of these molecules
Figure 7. MRI detection of SPION-labeled macrophages indicates hepatic localization. (A) Axial T2* maps of the abdomen were gener-
ated from eight echo times in mice before (baseline, day 0) and after (days 6, 13, 20 and 27) transplantation of 1 × 106 SPION-labeled
BMDMs into the hepatic portal vein. False-color maps show representative images per time point. Mice were scanned in the dorsal po-
sition (spinal column visible at the bottom of maps).The liver is positioned at the top of the scan (white arrows) with vasculature visible.
Kidneys are marked with the white arrowhead, and muscle tissue surrounding the spinal cord is marked with the white chevron. A drop in
liver T2* relaxation is characterized in the maps by a switch from green (baseline) to blue (post transplantation). (B) Three ROIs were
taken from each organ to quantify an average mean from pixel analysis on an animal per animal basis. Each organ is represented in the
panels showing a liver-specific drop inT2* time indicative of SPION-labeled BMDM localization. Consecutive MRI scans from the same
mice are connected by black line. P values are provided from statistical analysis where n ≥ 3, one-way analysis of variance.
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as cell tracking agents. Furthermore, other SPIONs
that are still under manufacture such as ferumoxytol
(Rienso, Feraheme) were not designed for cell label-
ing, so these are limited by suboptimal labeling
efficiency in macrophages.
Our group has recently described a technique to
generate SPIONs that harbor a functionalized dextran
polymer coating that can be tailored to control iron
uptake in stem cells [9]. In this work, we have inves-
tigated the effect of the particle chemistry to control
the physicochemical properties of the SPION. In this
way, we can identify the optimal particle character-
istics required for the most efficient labeling of
macrophages, a highly promising cell-based therapy
for liver disease [10] currently under evaluation in phase
I/II clinical trials (Macrophage therapy for Liver Cir-
rhosis, MATCH, Clinical Database Number 2015-
000963-15). First, we demonstrate that macrophages
of mouse and human origin can tolerate iron-labeling
using previously available clinically approved SPIONs,
resulting in negligible changes to cell health markers
(Figure 1). Ferumoxide provided substantial iron
uptake in cells (>5 pg Fe/cell, Figure 1C,F) whereas
ferumoxytol was less efficient at labeling BMDMs
(<2 pg/cell, Figure 1C). Ferumoxytol has been used
for MRI-based cell tracking, but labeling concentra-
tions of at least 500 μg/mL are required with the use
of transfection agents [24].These data confirmed that
BMDMs can tolerate iron concentrations required for
in vivo MRI detection.To improve iron-labeling effi-
ciency, we synthesized three SPIONs with different
coatings to confer a range of electrostatic charges (−11.6
mv to +19.6 mV).We observed that a positively charged
variant provided the best uptake but was limited by
cytotoxicity at high SPION concentrations
(Figure 2A,B). By altering the molar ratios of DEAE-
dextran to iron salt, we identified a SPION with a larger
hydrodynamic diameter that further improved iron
uptake (>10 pg Fe/cell), more so than any of the com-
mercial variants but, importantly, reduced cytotoxicity
(Figure 2D,E).
We further sought to reduce cytotoxicity by re-
ducing the labeling time from 24 h to 4 h. This
shortened protocol still provided substantial iron la-
beling (~5 pg Fe/cell) but vastly improved the
cytotoxicity profile in both mouse (Figure 3A–C) and
human macrophages (Figure 3K–M). Generally,
hMDMs appeared more sensitive than BMDMs to iron
labeling using the same SPION, but labeling at iron
concentrations of 25 μg Fe/mL and below was dem-
onstrated to be safe in macrophages from both species.
The molecular mechanisms that underpin SPION-
induced cytotoxicity are not well understood, but
several mechanisms have been proposed, including in-
duction of mitochondrial dysfunction and generation
of reactive oxygen species during iron catabolism [25].
Importantly for cell tracking, the iron label was re-
tained (>4 pg Fe/cell) for 7 days in vitro without any
evidence of cytotoxicity (Figure 3H–J) using the shorter
labeling protocol.
The ultimate aim of labeling macrophages in this
study is for use in regenerative therapy.Therefore, it
is imperative that they retain their function and phe-
notype after iron labeling. We assessed the effect of
labeling BMDMs with ferumoxytol and DEAE-Dex
1:4 on the phagocytic capacity of BMDMs (Figure 4).
We observed that ferumoxytol labeling caused a twofold
reduction in phagocytosis whereas DEAE-Dex 1:4 la-
beling had no effect despite providing 10 times more
iron uptake.Macrophages display a high degree of plas-
ticity, which has led to the adoption of a simplified
classification nomenclature; classical-activation (M1-
like) and alternative-activation (M2-like) [26]. Because
it may be important for macrophages to retain their
phenotypic plasticity to exert their therapeutic effect,
we investigated the effect of DEAE-Dex 1:4 labeling
on BMDM phenotype via quantification of cell surface
markers and gene expression analysis. The expres-
sion of CD86 (M1 marker) was increased, whereas
CD206 (M2 marker) was decreased after DEAE-
Dex 1:4 labeling indicating a shift toward an M1-
like phenotype (Figure 5).This was further evidenced
by the increased mRNA expression of M1 markers (IL-
1b, IL-12b and TNFα) and associated decrease in
expression of M2 markers (CD206 and Chi3L3)
(Figure 6). However, this shift toward an M1-like phe-
notype could be reversed through the subsequent
incubation of the SPION-labeled BMDMs with IL-4
as evidenced by a switch to a more M2-like gene ex-
pression profile.Taken together, these data suggest that
DEAE-Dex 1:4 labeling has no effect on the phago-
cytic function of BMDMs but shifts phenotype toward
a reversible M1-like phenotype which has been de-
scribed previously [27].
Finally, we performed a transplantation study in
healthy mice to test whether SPION-labeled BMDMs
could be detected via MRI using the cell number and
delivery route required for liver fibrosis therapy.We
utilized BMDMs obtained from mice that constitu-
tively express EGFP [16] (supplementary Figures S3
and S4) in BMDMs to confirm exogenous cell
localisation ex vivo. Importantly, the liverT2* time in
healthy mice was approximately 14 ms, which was con-
sistent throughout the liver and between animals,
providing a steady baseline measurement. However,
6 days after transplantation, we observed a twofold re-
duction in T2* time specifically in liver tissue in all
mice (Figure 7A,B).This drop inT2* time was uniform
throughout the liver, indicative of a homogenous dis-
tribution of BMDMs in the liver parenchyma. The
reduction inT2* time was maintained at days 13, 20
and 27.We show that both iron-positive and EGFP-
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positive cells are present in host liver tissue (Figure 8)
at days 6, 13 and 20 post-transplantation. However,
no exogenous cells were detected in liver paren-
chyma at 27 days, suggesting clearance of these cells
by unknown mechanisms, concordant with previous
observations [10].The fact that iron deposits were still
visualized in liver tissue at this time and thatT2* time
was not yet normalized suggests that SPIONs may have
transferred from transplanted cells to host cells as
BMDMs are cleared from the liver.This highlights one
limitation of using SPION-labeling for cell tracking:
free SPIONs (e.g., SPIONs released from necrotic
cells) are naturally cleared by the reticuloendothelial
system, including Kupffer cells [28], thereby provid-
ing the possibility of false-positive MRI hypointense
signals from host cells. It should also be noted that
SPIONs are biodegradable and therefore have a finite
lifetime in vivo becoming assimilated into the normal
blood pool within weeks [29]. Thus, SPION label-
ing is not a reliable cell-tracking technique for long-
term (>1 month) monitoring. It should also be noted
that MRI cannot be used for whole-body
biodistribution studies because luminal organs such
as lung and stomach do not provide reliable MRI
signals, whereas iron-rich organs (e.g., spleen) have
a very lowT2* time, vastly reducing the dynamic range
of hypointensity that can be provided by SPION-
labeled cells. Despite these inherent limitations, the
MRI contrast provided accurate localization of trans-
planted BMDMs in liver for 3 weeks in vivo.
In conclusion, by tuning the synthetic chemistry,
we have identified a novel SPION optimized for la-
beling macrophages of mouse and human origin
without the need for transfection agents.The SPION
contains a functionalized dextran polymer coating con-
taining DEAE, which provides a positive charge for
enhanced cell uptake, and fluorescein isothiocyanate,
a fluorescent moiety useful for a range of in vitro ap-
plications. Iron labeling using DEAE-Dex 1:4 was more
efficient than ferumoxytol, the only clinically ap-
proved SPION still manufactured. Furthermore, after
a safe labeling protocol was determined, hepatic
Figure 8. Ex vivo histochemical analysis confirms hepatic localization of transplanted BMDMs up to 3 weeks post-transplantation. (A)
Prussian blue staining shows small punctate spots of iron (blue deposits) throughout liver parenchyma at days 6, 13, 20 and 27 post-
transplantation (black arrows) against fast red counterstain, 40× magnification. (B) Immunofluorescent stains confirm hepatic localization
of GFP+ve cells (white arrows) in wild-type recipient frozen liver up to 20 days post-transplantation. No cells were detected at day 27,
suggesting transfer of iron from donor to host cells. No GFP signal was detected in either normal C57 BL6 frozen liver or antibody-
treated sections from normal frozen liver.The positive control showed strong membranous GFP staining in the livers of donor mice, confirming
appropriate antigen recognition using identical conditions.
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localisation of BMDMs could be monitored accu-
rately up to 3 weeks post-transplantation via MRI.
Further studies are now required to determine if
SPION-labeled BMDMs are functionally therapeu-
tic in the setting of liver disease. If this can be
demonstrated then this clinically approved class of con-
trast agents may represent a useful tool to monitor
safety and efficacy of macrophage therapy in patients.
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